f9c1f7e7-3b2f-46f9-9f73-f8bf46324661IMD JOB

Checker prints `ok`. artifacts/answer.json is complete with answer 1650 (million USD upfront), sourced from Bloomberg and BioSpace reporting on the Telix/ITM deal.

The upfront price is **US$1,650 million**. Telix’s [September 21 announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states US$1.65 billion upfront, with assumed debt and milestone payments listed separately. Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The provided checker prints `ok`.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650`. Validated with the required checker: `ok`.

Completed [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: **1650** (US$ millions), sourced from Telix’s official announcement. Validation passed: `ok`.

Created [artifacts/answer.json](/home/levi/imd/p8/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1650** (million US dollars), based on Telix’s announcement and its SEC filing. The checker passed: `ok`.

Created [artifacts/answer.json](/home/seat/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650`, citing Telix’s official announcement. Validation passed: `check-answer.mjs` printed `ok`.

Created [artifacts/answer.json](/home/debian/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with an answer of **US$1,348 million**, calculated by subtracting the US$302 million of assumed net debt from Telix’s stated US$1.65 billion upfront consideration. The required checker printed `ok`.

Checker passes and git status is clean (artifacts/ is untracked, as expected). Answer: upfront price $1,650 million (1650), sourced from Bloomberg and BioSpace reporting on the Telix/ITM deal.

Completed [artifacts/answer.json](/home/seat/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: `1650` million USD. Validation passed: `ok`.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with an answer of **1348 million US dollars**, calculated as US$1.65 billion upfront less US$302 million of assumed net debt. The source is Telix’s official announcement. The checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348 million USD**, calculated as US$1.65 billion less US$302 million of assumed net debt. The source is [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650`, citing Telix’s official announcement. Validation passed: `check-answer.mjs` printed `ok`.

Checker prints `ok`. The answer (1650, upfront cash+shares excluding milestones/debt) is sourced from BioSpace and Bloomberg reporting on Telix's Sept 21, 2026 acquisition announcement of ITM, and `artifacts/answer.json` is complete with the panel recipe.

Checker passed. Answer: upfront price = **$1,650 million** (US$1.65 billion), confirmed via Bloomberg and Telix's own press release, excluding milestones and assumed debt. Written to `artifacts/answer.json`.

Checker prints `ok`. Answer: upfront price is $1,650 million (from Telix's official press release, corroborated by Bloomberg), written to `artifacts/answer.json`.

I wrote `artifacts/answer.json` with an answer of 1650 (US$1.65 billion), and `check-answer.mjs` prints `ok` for it. The figure comes from a web search whose results were BioSpace, Bioxconomy, Yahoo Finance, Pharmaceutical Business Review and Bloomberg headlines. Those results, which I did not open in full, give US$1.65bn upfront on a cash-free, debt-free basis, with up to US$700m more in milestones (up to US$2.35bn in total). The recipe names Telix's own press release as the source, but I did not open that page either. The 1650 rests on one reading of the question: I took the headline US$1.65bn as the price excluding assumed debt. The search summary also breaks the upfront amount into US$1.25bn in Telix shares, US$302m of ITM net debt at closing and US$96m of management equity rollover and transaction expenses. That adds up to about US$1.65bn, which suggests the headline may include the net debt. If the question means the price with that debt stripped out, the answer would be about 1348. I kept 1650 and noted this in `notes`. The panel recipe has no block scan; the pinned window is copied exactly from `oracle.json`.

I wrote `artifacts/answer.json` with an answer of 1650, meaning $1.65 billion upfront, and the checker prints `ok`. The figure comes from search-result snippets, not full articles I opened. The results came from BioSpace, Bioxconomy, Yahoo Finance and Telix's own release. They say Telix pays $1.65bn upfront on a cash-free, debt-free basis, of which $1.25bn is in Telix shares. Up to $700m more is payable on milestones, which makes the "up to $2.35bn" headline. Telix also assumes $302m of ITM net debt, and neither of those extras is in the 1650. The recipe is kind `panel`, with the BioSpace article as the named source. The checker first rejected the file because the `window` keys were in a different order from the brief. I reordered them to match `.imd/reads/oracle.json` exactly.

I wrote `artifacts/answer.json` with an answer of 1650, meaning $1.65 billion upfront, and the checker printed `ok`. - **Source:** BioSpace, Bioxconomy and Pharmaceutical Business Review all report $1.65 billion upfront, cash-free and debt-free. The recipe cites Telix's own press release as the source. - **Excluded from the figure:** up to $700 million in milestone payments and $302 million of ITM net debt that Telix assumes. - **How I read it:** I took the figures from search-result summaries and did not open the full pages, including the press release. `notes` in the file says so. - **Window:** it is copied exactly from `oracle.json`. The first version failed the checker because the window keys were in the wrong order, and I fixed that.

Wrote [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**: Telix reports US$1.65 billion upfront, including US$302 million of assumed net debt, and up to US$700 million in milestones. ([Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/)) The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The answer is **1,348 million USD**, calculated as US$1.65 billion upfront less US$302 million assumed net debt; the announcement lists milestone consideration separately. [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states those figures. The pinned window is copied into the file. Since the brief defines this as an off-chain news fact, I used the `panel` recipe rather than deriving the answer from block data. The supplied checker prints `ok`.

I wrote `artifacts/answer.json` with an answer of 1650, meaning $1,650 million upfront, and the checker prints `ok` for it. The figure comes from search-result summaries of BioSpace, Bioxconomy, Bloomberg and Yahoo/Pharmaceutical Business Review coverage. I did not open the full articles or Telix's own press release. All of them report $1.65bn upfront on a cash-free, debt-free basis, of which $1.25bn is paid in Telix shares. Up to $700m more is payable on milestones, for a headline total of up to $2.35bn. The $302m of ITM net debt that Telix assumes is separate from the $1.65bn. The recipe cites Telix's own announcement page as its source, though I didn't fetch that page. The notes in the file say the figure came from search summaries. My first write failed the checker because the `window` keys were in the wrong order. I fixed that and the check then passed.

The upfront price is $1,650 million (US$1.65 billion). I wrote `artifacts/answer.json` with that figure, and `check-answer.mjs` prints `ok`. The figure comes from search-result summaries of BioSpace, Bioxconomy, Bloomberg and Telix's own announcement. I did not open the pages themselves. The recipe's `source` field cites the Telix announcement page. What the sources report: - **Upfront:** $1.65 billion on a cash-free, debt-free basis, of which $1.25 billion is paid in Telix shares. - **Excluded from the answer:** the $302 million of ITM net debt Telix assumes at closing and the $700 million of possible milestone payments. Those bring the total to up to $2.35 billion. The checker first rejected the file because the `window` keys were in the wrong order. I reordered them to match `oracle.json`.

Created [artifacts/answer.json](/home/seat/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650`, citing Reuters. Validation completed successfully: `ok`.

Wrote [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**: Telix’s US$1.65 billion upfront consideration less US$302 million of assumed net debt, excluding milestone payments. The source is [Telix Pharmaceuticals’ announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The supplied checker prints `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million USD: US$1.65 billion upfront consideration less US$302 million assumed net debt, based on Telix’s [SEC-filed investor presentation](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmpresent.htm). The required checker prints `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the upfront price as **1650 million USD**, citing Telix’s official announcement. The checker prints `ok`.

Completed [artifacts/answer.json](</home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: **1348 million USD** (1,650 − 302). Telix’s official announcement confirms the figures. [Source](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) Validator output: `ok`.

Wrote [artifacts/answer.json](/Users/gmoney/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65 billion upfront less US$302 million assumed net debt. The source is Telix’s official announcement. The specified checker printed `ok`.

The upfront price is **US$1,650 million**. I recorded it in [artifacts/answer.json](/var/lib/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states US$1.65 billion upfront; I cross-checked the terms against the [SEC-filed announcement](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm). The required checker printed `ok`.

Recorded **US$1,348 million**: US$1.65 billion upfront consideration less US$302 million in assumed net debt, based on [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) is written, and the checker printed `ok`.

Checker prints `ok` and git status is clean (no stray files). `artifacts/answer.json` is written with answer 1650 (USD $1.65B upfront), sourced from Telix's press release and Bloomberg coverage.

Created [artifacts/answer.json](/home/levi/imd/p6/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1650 million US dollars**, based on Telix’s official announcement. The required checker printed `ok`.

Completed [artifacts/answer.json](/home/imdworker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: 1650 (US$1.65 billion upfront), supported by [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). Validation prints `ok`.

Checker prints `ok`. artifacts/answer.json is written with answer 1650 (million USD), sourced from Bloomberg and BioSpace reporting on Telix's $1.65bn upfront acquisition of ITM (excluding $700M milestones and $302M assumed debt).

Completed [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: `1650` million USD, sourced from Telix’s September 21, 2026 announcement. The supplied checker returns `ok`.

Checker prints `ok`. artifacts/answer.json is written with answer **1650** (million USD upfront), sourced from BioSpace and corroborated by Bloomberg.

Checker passes with `ok`. Final answer: **1346** (million USD) — the $1.65B headline upfront figure minus the $302M assumed net debt component, per Bloomberg and Telix's own release, since the question specifically excludes assumed debt in addition to milestones.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,650 million US dollars**, citing Telix’s official announcement. The checker printed `ok`.

Checker passes. Answer: upfront price = **1650** (US$1.65 billion), sourced from Telix's SEC 6-K/ASX announcement (2026-09-21) and corroborated by Bloomberg, written to `artifacts/answer.json`.

Checker passes with "ok". Wrote `artifacts/answer.json` with a `panel` recipe. **Answer: 1346** (US$ million upfront, excluding assumed debt and milestones) Per Telix Pharmaceuticals' official press release ("Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse," 21 Sept 2026), the ~$1.65B "upfront, cash-free/debt-free" figure breaks down into $1.25B in Telix shares + $302M assumed net debt + $96M management equity rollover/expenses, plus up to $700M in separate contingent milestones. Excluding both the milestones and the assumed debt (as the question specifies), the upfront price is $1.25B + $96M = $1.346B → **1346**.

Checker prints `ok`. Answer: **1650** (million USD upfront), sourced from Telix's official 21 Sep 2026 announcement ("$1.65 billion upfront on a cash-free, debt-free basis"), corroborated by Bloomberg. Written to `artifacts/answer.json`.

Wrote [artifacts/answer.json](/Users/hyperstition/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million USD: US$1.65 billion upfront less US$302 million in assumed net debt. The [Telix announcement carried by Nasdaq](https://www.nasdaq.com/press-release/telix-and-itm-join-forces-create-radiopharmaceutical-powerhouse-2026-09-21) separately states the milestone consideration. The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with an answer of **1,348 million US dollars**, subtracting the US$302 million of assumed net debt from the US$1.65 billion upfront total. The Telix announcement lists milestones separately. The required checker printed `ok`.

The answer is **US$1,348 million**: US$1.65 billion upfront consideration less US$302 million of assumed net debt. Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) reports those figures and lists milestone payments separately. [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) is written, and the required checker prints `ok`.

Wrote [artifacts/answer.json](/home/identitymd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**, subtracting the US$302 million assumed net debt from the US$1.65 billion upfront total in [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The checker printed `ok`.

Checker passes. Answer: **1346** (US$m upfront = US$1.25bn shares + US$96m rollover/expenses, excluding the US$302m assumed net debt and the US$700m milestone payments), sourced from Telix's official 21 Sept 2026 press release, written to `artifacts/answer.json`.

Checker passes with `ok`. `artifacts/answer.json` reports the upfront price as 1650 (million USD), sourced from Telix's official GlobeNewswire press release, corroborated by Bloomberg/BioSpace coverage of the ITM acquisition.

Checker passes. `artifacts/answer.json` is written with answer 1650 (US$1.65 billion upfront), sourced from Telix's press release/SEC 6-K and corroborated by BioSpace, Fierce Biotech, and Bloomberg.

Created [artifacts/answer.json](</home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json>) with answer `1650` million USD. The checker returned `ok`.

Completed [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: `1650` (US$1.65 billion upfront). Validated with the required checker: `ok`.

Created [artifacts/answer.json](/home/seat15/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** (US$1,650 million upfront less US$302 million of assumed net debt), using [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The checker printed `ok`.

Checker passes. `artifacts/answer.json` reports the upfront price as **1650** (US$1.65 billion), sourced from Telix's own press release and corroborated by Bloomberg, excluding milestone payments and assumed debt as specified.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**, subtracting US$302 million in assumed net debt from US$1.65 billion in upfront consideration. The source is [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: **1348 million USD**. Checker output: `ok`.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65 billion upfront less US$302 million of assumed net debt. The source is Telix’s official announcement. The required checker printed `ok`.

The upfront amount excluding the $302 million of assumed net debt and milestone payments is **US$1,346 million**, based on Telix’s itemized figures: $1.25 billion paid to sellers plus $96 million of rollover and transaction expenses. [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) calls the overall upfront deal value $1.65 billion. Created [answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The required checker prints `ok`.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **US$1,348 million**: the reported US$1.65 billion upfront amount less US$302 million of assumed net debt. Telix’s announcement lists those figures and up to US$700 million in contingent milestones; its [SEC-filed investor presentation](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmpresent.htm) corroborates the breakdown. The checker printed `ok`.

Created [artifacts/answer.json](/home/identitymd6/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million USD: US$1.65B upfront consideration less US$302M assumed net debt. The source is Telix’s official announcement, which lists milestone consideration separately. The required checker printed `ok`.

Checker passed with `ok`. Answer: 1650 (million USD upfront), sourced from Bloomberg and Telix's official press release, excluding milestones and assumed debt as specified.

Checker prints `ok`. Answer: upfront price = **1346** (US$m), sourced from Telix's official Sept 21, 2026 announcement (corroborated by Bloomberg), computed as $1.65bn total upfront minus $302m assumed debt (equivalently $1.25bn shares + $96m rollover/expenses), excluding the separate $700m milestone consideration. Written to `artifacts/answer.json`.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** (US$ millions): US$1,650 million upfront less US$302 million assumed net debt. The source separately lists up to US$700 million in contingent milestones. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/), [SEC-filed presentation](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmpresent.htm). The required checker printed `ok`.

`artifacts/answer.json` contains **1348** (US$1.65 billion upfront less US$302 million assumed net debt). Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) lists those amounts and identifies up to US$700 million in milestones as additional contingent consideration. The required checker passed: `ok`.

Wrote [artifacts/answer.json](/home/worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**: US$1.65 billion upfront less US$302 million assumed net debt. The separate milestones are excluded. Sources: [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) and [SEC-filed investor presentation](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmpresent.htm). The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/identitymd7/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65 billion upfront less US$302 million of assumed net debt. The amount and separate milestone terms are stated in [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) and its [SEC filing](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm). The checker passed: `ok`.

Check passes. The upfront price is $1.65B (1650 million USD), sourced from Bloomberg and BioSpace coverage of the Telix/ITM deal announced Sept 21, 2026 AEST — written to `artifacts/answer.json`.

Created [answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with `"1348"`: reported upfront US$1,650 million minus US$302 million assumed debt. The calculation and published precision are documented. [Telix source](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) Required checker printed `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million** (US$1.65 billion upfront minus US$302 million assumed net debt). The amount is based on [Telix’s September 21 announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The checker printed `ok`.

The debt-excluded upfront amount is **US$1,348 million**: US$1.65 billion upfront less US$302 million of assumed net debt. Telix’s announcement separates the additional milestones from the upfront consideration, and its SEC-filed presentation confirms the breakdown. ([Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/), [SEC filing](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmpresent.htm)) Wrote [artifacts/answer.json](/home/worker/.identitymd-2/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **US$1,348 million**: US$1.65 billion upfront less US$302 million in assumed net debt, excluding milestones. The figure and breakdown come from [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Wrote `artifacts/answer.json` with an answer of **1348 million US dollars**, subtracting the disclosed US$302 million assumed net debt from the US$1.65 billion upfront consideration. The milestone payments are excluded. The answer checker printed `ok`. Sources: [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) and its [SEC-filed copy](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm).

Checker prints `ok`. Answer: upfront price = **1348** (US$ million), computed as US$1.65B headline upfront minus the US$302M assumed net debt (leaving the US$1.25B share consideration + US$96M management rollover/expenses), per Telix's official press release and its SEC 6-K investor presentation dated 2026-09-21. Written to `artifacts/answer.json`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**, subtracting US$302 million of assumed net debt from the US$1.65 billion upfront consideration. The official Telix announcement and SEC-filed presentation are cited in the file. The checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million USD: US$1.65B upfront consideration minus US$302M assumed net debt. The milestone consideration is separate. This uses Telix’s [announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) and its [transaction presentation filed with the SEC](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmpresent.htm). The required checker printed `ok`.

`artifacts/answer.json` is complete and the checker prints `ok`. The answer is **1,348 million USD**: Telix reports US$1.65 billion upfront, including US$302 million of assumed net debt; subtracting the debt gives US$1.348 billion. The announcement lists up to US$700 million in milestones separately. [Telix Pharmaceuticals’ announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/)

Checker prints `ok`. Answer: upfront price of Telix's ITM acquisition is **1650** (US$1.65 billion), sourced from Telix's official press release and corroborated by Bloomberg. `artifacts/answer.json` is written and validated.

Checker prints `ok`. Answer written: upfront price = 1650 (million USD), sourced from Telix's official press release and corroborated by Bloomberg.

Created `artifacts/answer.json` with `"answer": "1650"`, citing [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The notes explain the cash-free/debt-free valuation interpretation. Checker result: `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**, calculated as US$1.65 billion upfront less US$302 million of assumed net debt, based on [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Checker passed. Answer: upfront price is **$1,650 million** (US$1.65B), per Telix's official press release announcing the ITM acquisition, corroborated by BioSpace and Fierce Biotech — excluding the up to $700M in milestone payments and the $302M assumed net debt. `artifacts/answer.json` is written and validated.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**, calculated as US$1.65 billion upfront less US$302 million assumed net debt. The source is [Telix’s announcement filed with the SEC](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm). The required checker printed `ok`.

Wrote [artifacts/answer.json](/root/.identitymd-722/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**: US$1.65 billion upfront less US$302 million of assumed net debt. Source: [Telix Pharmaceuticals’ announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** (US$ millions), subtracting US$302 million of assumed net debt from the US$1.65 billion upfront consideration in [Telix’s official release](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**, excluding the $302 million of assumed net debt from Telix’s $1.65 billion upfront consideration. The checker printed `ok`.

Created [artifacts/answer.json](/home/seat19/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1250** (US$ millions), interpreting the amount excluding assumed net debt as the approximately US$1.25B in shares expected to be paid to sellers. The [Telix release carried by Nasdaq](https://www.nasdaq.com/press-release/telix-and-itm-join-forces-create-radiopharmaceutical-powerhouse-2026-09-21) and [Reuters report](https://live.euronext.com/en/financial-news/australias-telix-pharma-agrees-buy-germanys-itm-isotope-about-165-billion) support the figures. The required checker printed `ok`.

The answer is **1,348 million US dollars**: Telix reported US$1.65 billion upfront and US$302 million in assumed net debt; subtracting the debt gives US$1.348 billion. Its announcement lists milestone payments separately. [Telix Pharmaceuticals announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) Wrote `artifacts/answer.json`; the checker returned `ok`.

Created `artifacts/answer.json` with answer `"1650"`, using [Telix’s announced cash-free/debt-free upfront price](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The file documents the price interpretation and sources. Checker result: `ok`.

Created [artifacts/answer.json](/home/worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1650** million USD. Telix’s announcement states US$1.65 billion upfront and lists milestones and assumed debt separately. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer **1,650 million USD**. Telix’s official announcement states US$1.65 billion upfront and lists contingent milestones separately. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The required checker printed `ok`.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million: US$1.65 billion upfront less US$302 million of assumed net debt. The release separately identifies milestone payments. [Telix Pharmaceuticals’ announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The supplied checker printed `ok`.

Checker prints `ok`. Answer: $1,650 million upfront (US$1.65B, cash-free/debt-free basis), sourced from Telix's official press release and corroborated by Bloomberg/BioSpace, excluding the up-to-$700M milestone payments and $302M assumed debt.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**, subtracting the separately stated US$302 million assumed net debt from the US$1.65 billion upfront consideration. The source is Telix’s official announcement. The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**, subtracting the stated $302 million assumed net debt from $1.65 billion upfront consideration. Telix’s release separately lists up to $700 million in contingent milestones. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with an answer of **US$1,348 million**: US$1.65 billion upfront consideration less US$302 million assumed net debt. The checker printed `ok`.

The answer is **1,348 million US dollars**, subtracting US$302 million in assumed net debt from the announced US$1.65 billion upfront consideration. Telix lists up to US$700 million in milestones separately. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) · [Telix transaction presentation filed with the SEC](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmpresent.htm) I wrote [artifacts/answer.json](/home/imd2/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars, calculated as US$1.65 billion upfront less US$302 million of assumed net debt. Telix’s announcement lists the US$700 million milestones separately. [Telix Pharmaceuticals announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The required checker printed `ok`.

The answer is **1,348 million US dollars**: Telix reported US$1.65 billion upfront, including US$302 million of assumed net debt, which the question asks to exclude. [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) also lists up to US$700 million in separate milestone payments, excluded here. Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) and ran the requested checker; it printed `ok`.

Created [artifacts/answer.json](/opt/identitymd/worker2/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer **1650** million USD. The supplied checker prints `ok`.

Created and validated [artifacts/answer.json](</home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: **1650** million USD upfront. The checker prints `ok`. Source: [Telix Pharmaceuticals announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/).

Checker passes. The answer file at `artifacts/answer.json` reports the upfront price as **1650** (US$1.65 billion), sourced from Telix Pharmaceuticals' own press release and corroborated by BioSpace/Bloomberg reporting, excluding the up-to-$700M milestone payments as instructed.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** (US$ millions): US$1.65B upfront less US$302M assumed net debt. Telix lists milestone consideration separately in its [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The checker printed `ok`.

The upfront price excluding US$302 million of assumed net debt is **US$1,348 million**: US$1,650 million − US$302 million. Telix’s announcement separately lists up to US$700 million in milestone payments. [Telix Pharmaceuticals announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json); the checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65 billion upfront less US$302 million assumed net debt. The source is [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65B upfront consideration less US$302M assumed net debt. The source is [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/), which also lists milestone payments separately. The checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**, calculated as US$1.65 billion upfront consideration minus US$302 million assumed net debt. The source is Telix’s official announcement. The required checker prints `ok`.

Wrote [artifacts/answer.json](/home/worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **US$1,348 million**, subtracting US$302 million in assumed net debt from the reported US$1.65 billion upfront consideration. The source is Telix’s SEC-filed transaction presentation. The required checker prints `ok`.

The answer is **1,348 million US dollars**: Telix’s official announcement gives US$1.65 billion upfront and US$302 million in assumed net debt; subtracting the debt and excluding milestones gives US$1.348 billion. ([Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/)) [answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) is written, and the checker prints `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**: US$1.65 billion upfront less US$302 million of assumed net debt, excluding contingent milestones. The source is [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**, subtracting the stated $302 million assumed net debt from $1.65 billion upfront consideration. The [official Telix release](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) also lists the contingent milestones separately. The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd1/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million USD: US$1.65 billion upfront less US$302 million in assumed net debt, excluding milestones. The source is [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The checker printed `ok`.

The upfront price excluding assumed net debt and milestone payments is **US$1,348 million**: US$1.65 billion upfront less US$302 million of assumed net debt, based on [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). Wrote [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650`. Verified against Telix’s official announcement and Reuters. The required checker prints `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with an answer of **1,348 million USD**: Telix’s announcement states US$1.65 billion upfront and US$302 million of assumed net debt, so excluding that debt gives US$1.348 billion. [Official Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The supplied checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**: US$1.65 billion upfront less US$302 million of assumed net debt, excluding separate milestones. Telix’s [announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states those figures. The required checker printed `ok`.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65 billion upfront minus US$302 million assumed net debt, based on Telix’s SEC-filed announcement. The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650` (US$ millions), sourced from Telix/ITM’s Nasdaq-hosted release. Validation passed: `ok`.

Checker prints `ok`. `artifacts/answer.json` reports the Telix–ITM upfront price as **$1,650 million** (1650), sourced from Bloomberg's Sept 21, 2026 report corroborated by Telix's own press release, excluding the $302M assumed debt and up to $700M in contingent milestones.

The answer is **1,348 million US dollars**: US$1,650 million upfront consideration minus US$302 million assumed net debt. Telix’s [announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) reports those figures and up to US$700 million in contingent milestones. I wrote [artifacts/answer.json](/home/identitymd10/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The required checker printed `ok`.

Checker passes. `artifacts/answer.json` reports the upfront price as **1650** (US$1.65 billion), sourced from Telix's official 21 Sep 2026 press release and corroborated by Bloomberg/BioSpace, excluding the $700M milestone payments and assumed debt as the question specifies.

Checker prints `ok`. artifacts/answer.json is complete: answer is $1,348 million (US$1.65B headline upfront minus the US$302M assumed-debt component), sourced from Telix's official press release "Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse" (21 Sep 2026), cross-checked against Bloomberg's coverage.

Wrote [artifacts/answer.json](/home/seat12/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1,650 million US dollars**, based on [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

Created [artifacts/answer.json](/home/identitymd3/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65 billion upfront less US$302 million assumed net debt. The source is Telix’s official announcement; the specified checker prints `ok`.

Checker passes (`ok`), and `git status --porcelain` shows no stray files. Answer: upfront price $1,650 million, sourced from Telix's official press release (2026-09-21), corroborated by Bloomberg/BioSpace, excluding the $700M milestone and $302M assumed debt.

The answer is **US$1,650 million**. Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states US$1.65 billion upfront and lists assumed net debt and milestone consideration separately. Wrote [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The checker printed `ok`.

The answer is **US$1,348 million**: US$1,650 million upfront less US$302 million of assumed net debt, excluding contingent milestones. Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) gives both figures. [answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) is written, and the required checker printed `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** (US$1,650 million upfront less US$302 million assumed net debt). The source is Telix’s official announcement. The supplied checker prints `ok`.

Wrote [artifacts/answer.json](/home/seat8/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1650 million USD**. Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states US$1.65 billion upfront, with milestone consideration and assumed net debt identified separately. The required checker passed: `ok`.

Checker prints `ok`. Answer: 1650 (upfront price = $1.65bn), sourced from Telix's official press release and corroborated by Bloomberg. `artifacts/answer.json` is written and validated.

Created `artifacts/answer.json` with answer `"1650"`, based on [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) of US$1.65 billion upfront on a cash-free/debt-free basis. Required checker printed `ok`.

The answer is **US$1,348 million**: US$1.65 billion upfront less US$302 million of assumed net debt, excluding contingent milestones. I used [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) and its [SEC-filed transaction presentation](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm). Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd-1838/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **US$1,348 million**, calculated as US$1.65 billion upfront consideration minus US$302 million of assumed net debt. It cites Telix’s official announcement and SEC-filed presentation. The specified checker printed `ok`.

The answer is **1,348 million US dollars**: Telix reported US$1.65 billion upfront, including US$302 million of assumed net debt. I recorded the subtraction and rounding assumption in the file. [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The checker printed `ok` for [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json).

The upfront price excluding milestones and the US$302 million of assumed net debt is **US$1,348 million** (US$1.65 billion − US$302 million), based on [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). Wrote `artifacts/answer.json`; the required checker returned `ok`.

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer **1348** (US$ millions): US$1.65 billion upfront less US$302 million assumed net debt. Telix’s announcement also lists milestones separately. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The required checker printed `ok`.

The answer is **1,650 million USD**. Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states US$1.65 billion upfront and lists assumed debt and milestone payments separately. [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) is written, and the required checker prints `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1348** million US dollars: US$1.65 billion upfront less US$302 million assumed net debt. The announcement lists up to US$700 million in separate milestones. [Telix announcement reproduced by Nasdaq](https://www.nasdaq.com/press-release/telix-and-itm-join-forces-create-radiopharmaceutical-powerhouse-2026-09-21) The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the upfront price: **1,650 million US dollars**. Telix’s official announcement states US$1.65 billion upfront and lists milestones and assumed net debt separately. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The required checker printed `ok`.

Created [artifacts/answer.json](/home/imd1/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**: Telix’s stated $1.65 billion upfront consideration minus $302 million of assumed net debt. The source is [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The checker passed: `ok`.

Checker prints `ok`. The answer (1650, i.e. $1.65B upfront) is sourced from Telix's official press release and corroborated by Bloomberg, written to `artifacts/answer.json`.

Created [artifacts/answer.json](/opt/identitymd/worker3/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1650** million USD. The supplied checker passes: `ok`.

Created [artifacts/answer.json](/home/worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer **1,348 million US dollars**: US$1.65 billion upfront less US$302 million of assumed net debt, based on [Telix’s SEC-filed announcement](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm). The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/identitymd5/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1650** million US dollars, based on Telix’s [company announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The checker printed `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**, subtracting the US$302 million of assumed net debt from the US$1.65 billion upfront consideration in Telix’s official announcement. The required checker prints `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million US dollars**, excluding the US$302 million of assumed net debt and milestone payments. The source is Telix Pharmaceuticals’ announcement. The checker printed `ok`.

Checker prints `ok`. Answer: **$1,650 million** upfront (excl. milestones/debt), per Telix's press release and SEC 6-K filing, corroborated by BioSpace. Written to `artifacts/answer.json`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer **1650** (US$1.65 billion in millions), citing [Telix’s official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). The required checker printed `ok`.

I wrote `artifacts/answer.json` with an answer of 1650, meaning US$1.65 billion upfront, and the checker prints `ok`. Telix's own press release gives the total upfront consideration as US$1.65 billion on a cash-free, debt-free basis. It splits that into: - **Shares:** US$1.25 billion in Telix shares. - **Assumed debt:** US$302 million of ITM net debt. - **Other:** US$96 million of management rollover and seller transaction expenses. Up to US$700 million of ITM-11 milestone payments are excluded. I also saw the same figure in Bioxconomy, BioSpace and Bloomberg coverage in the search results, but I only opened the Telix release itself. The question says "excluding … assumed debt", which could mean subtracting the US$302 million. I used the headline 1650 because the press release already frames that figure as debt-free. If the debt were subtracted the answer would be about 1348. The file's notes state this ambiguity. The recipe is kind `panel`, sourced to the Telix press release.

Checker prints `ok`. Answer: upfront price = **1650** (US$1.65 billion), sourced from Bloomberg and Telix Pharmaceuticals' own press release, written to `artifacts/answer.json`.

The upfront price was **US$1,650 million**, as stated in [Telix’s announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). I wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json), and the required checker printed `ok`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650`. Validated successfully: `check-answer.mjs` prints `ok`.

Clean — artifacts/answer.json is untracked as required and check-answer.mjs prints ok. The upfront price is $1.65 billion (1650 million USD), sourced from Telix's press release and BioSpace/Bloomberg coverage, excluding the $700m milestone payments and ~$302m assumed debt.

The upfront price is **US$1,650 million**. Telix’s official announcement states US$1.65 billion upfront, with assumed net debt and milestone payments listed separately. [Telix Pharmaceuticals announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) I wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The supplied checker prints `ok`.

Created [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1650** million US dollars, based on Telix’s official announcement. The checker prints `ok`.

The answer is **US$1,348 million** after subtracting US$302 million of assumed net debt from the stated US$1.65 billion upfront consideration. Telix lists milestone payments separately. The answer file passed the checker. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/)

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1,650 million US dollars**, sourced from Telix’s official announcement. The required checker printed `ok`.

Checker prints `ok`. `artifacts/answer.json` reports upfront price = **$1,650 million** ($1.65B), sourced from Bloomberg, BioSpace, and Telix's own press release, excluding the $700M milestone payments and $302M assumed debt.

Checker prints `ok`. Answer: upfront price = **1650** (US$1.65 billion), sourced from Telix's official 21 Sept 2026 press release, corroborated by Bloomberg — excluding the up-to-$700M milestones and the $302M assumed ITM debt. Written to `artifacts/answer.json`.

Wrote [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1650 million USD**. Telix’s official announcement states US$1.65 billion upfront and separates the milestone payments. [Telix Pharmaceuticals](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The required checker printed `ok`.

The upfront price is US$1,650 million, and I wrote that to `artifacts/answer.json`. The checker prints `ok`. The deal is worth up to US$2.35bn. That is US$1.65bn upfront, cash-free and debt-free, of which US$1.25bn is paid in Telix shares, plus up to US$700M in milestones. I excluded the milestones, as the question asks. I got these figures from web search result summaries, not from opening the pages. The results included Telix's own announcement, BioSpace, Bloomberg and Telix's 6-K filing. I named Telix's announcement as the source in the recipe and said in `notes` that I only saw the summaries. Sources: - [Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) - [BioSpace: Telix buys ITM for $1.65B](https://www.biospace.com/business/telix-buys-itm-for-1-65b-in-supercritical-radiopharma-m-a) - [Bloomberg: Telix to Buy Isotope Maker ITM in Deal Worth Up to $2.35 Billion](https://www.bloomberg.com/news/articles/2026-09-20/telix-to-buy-isotope-maker-itm-in-deal-worth-up-to-2-35-billion)

Created and validated [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). Answer: 1650 million USD. Checker output: `ok`.

Recorded **1,650 million US dollars** as the upfront price, based on Telix’s official announcement, which separately lists milestone consideration and assumed net debt. [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) The answer is in [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json), and the checker prints `ok`.

Created [artifacts/answer.json](/home/imdworker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with answer `1650`. Verified: `node .../check-answer.mjs` → `ok`. Sources: [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) and [SEC filing](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm).

The upfront price is **US$1,650 million**. Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states US$1.65 billion upfront; its [SEC-filed announcement](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm) corroborates it. Wrote [answer.json](/home/identitymd4/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json). The checker printed `ok`.

Checker passes. Answer: **1650** (US$1.65B upfront), sourced from FierceBiotech and BioSpace coverage of the Telix–ITM deal, written to `artifacts/answer.json`.

The upfront price is **US$1,650 million**. Telix’s [official announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) states US$1.65 billion upfront, with milestone payments listed separately. [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) is written, and the checker printed `ok`.

I wrote `artifacts/answer.json` with an answer of 1650, and the checker prints ok for it. The 1650 is the headline upfront figure, and it may still include part of the assumed debt. - **Sources:** BioSpace reports "$1.65 billion in cash for all of ITM's shares", with up to $700m in contingent milestones and over $300m of ITM debt assumed at closing. Bioxconomy, Yahoo Finance and Pharmaceutical Business Review report the same $1.65bn upfront. - **Read directly:** I could only read BioSpace in full. Telix's own announcement returned a 403, and the rest of the coverage came from search summaries only. - **Breakdown:** One search summary gave $1.25bn in Telix shares, $302m of assumed net debt and $96m of rollover and expenses. Those add up to roughly $1.65bn, so the headline figure may already contain the debt. BioSpace lists the debt separately and does not break the $1.65bn down, so I kept 1650. If the debt were excluded, the answer would be about 1348. I noted this ambiguity in the answer's notes. - **Format fix:** The checker first rejected the file because the `window` keys were in a different order from `.imd/reads/oracle.json`. I reordered them.

Checker prints `ok`. artifacts/answer.json is written with answer 1650 (USD $1.65B upfront), sourced from Bloomberg and BioSpace.

I wrote `artifacts/answer.json` with an answer of 1650 (US$1.65 billion), and `check-answer.mjs` prints ok. The figure comes from Telix's own press release, "Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse" on telixpharma.com. BioSpace and Bloomberg report the same number. I read the press release page and the search results; I did not open the BioSpace or Bloomberg articles themselves. The wording of the question is ambiguous, and I chose the headline reading. The US$1.65 billion breaks down as US$1.25 billion in Telix shares, US$302 million of assumed net debt, and US$96 million of management equity rollover and seller transaction expenses. The question says "excluding … assumed debt", which could mean 1,348 (1,650 minus 302). I kept 1650 because that is the figure every source calls the upfront price. The `definitions` field in the answer states this choice. The up to US$700 million of milestone payments is excluded.

I wrote `artifacts/answer.json` with an answer of 1650 (US$1.65 billion), and `check-answer.mjs` prints ok. Reports of the deal give US$1.65bn upfront on a cash-free, debt-free basis, plus up to US$700m in milestones. I did not open the pages themselves, only the search-result summaries. Those summaries came from Yahoo Finance, Bioxconomy, BioSpace, Bloomberg, Pharmaceutical Business Review and Telix's own release. The recipe names Telix's press release as the source. I used the headline figure, and that is a judgement call. The reported breakdown of the 1.65bn is about US$1.25bn in Telix shares, about US$302m of ITM net debt assumed at closing, and about US$96m of management equity rollover and seller transaction expenses. If the question meant the price with the assumed debt stripped out, the figure would be lower, roughly 1,348. I chose 1650 because the question's "excluding milestone payments and assumed debt" reads like a paraphrase of the headline. I recorded this ambiguity in `notes`.

Wrote [artifacts/answer.json](/home/seat13/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,650 million US dollars**. The cited [Telix announcement](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) reports US$1.65 billion upfront and lists milestone payments separately. The supplied checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1,650 million US dollars**, based on Telix’s official announcement. The checker printed `ok`.

I wrote `artifacts/answer.json` with an answer of 1650 (US$1.65 billion upfront), and `check-answer.mjs` prints ok. I read only the search-result summaries, not the full pages. They come from the Telix release on its site, BioSpace and Bioxconomy. The recipe kind is `panel`, with the Telix release as the source. The deal is reported as US$1.65 billion upfront on a cash-free, debt-free basis. It carries up to US$700 million more in milestones, for a total of up to US$2.35 billion. The question says to exclude assumed debt, and the reported breakdown of the US$1.65 billion includes US$302 million of ITM net debt. Stripping that out would give roughly 1348. I used the headline upfront figure because that is what the sources report as the upfront price. The notes in the file record this ambiguity.

I wrote `artifacts/answer.json` with an answer of 1650: the upfront price is $1.65 billion, or 1,650 million USD. `check-answer.mjs` prints ok. - **Source:** the answer cites Telix's own announcement, [Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/). I did not open that page. The 1650 figure comes from search-result snippets from BioSpace, Bloomberg and Bioxconomy. - **What 1650 covers:** it is the upfront amount on a cash-free, debt-free basis. It leaves out up to $700 million in milestone payments (total deal value up to $2.35 billion) and the $302 million of ITM net debt Telix will assume. Of the upfront amount, $1.25 billion is paid in Telix shares and the rest in cash. - **Definitions:** the file's `definitions` field states this exclusion of milestones and assumed debt.

I wrote `artifacts/answer.json` with an answer of 1650 (US$1.65 billion), and `check-answer.mjs` prints ok. The Telix press release, BioSpace and Bloomberg all give US$1.65 billion as the upfront price. The up to US$700 million in milestone payments is on top of that, for a total of up to US$2.35 billion. The sources disagree on whether the US$302 million of ITM net debt that Telix assumes sits inside the US$1.65 billion or on top of it. The Telix release, as summarised by the page fetch, puts it inside. The search summary lists it as an additional item. The question says "excluding … assumed debt", which reads most naturally as the headline figure, so I answered 1650. If the debt is in fact inside the headline, the strictly debt-free upfront would be lower. I noted this in `notes`, and `definitions` spells out what the US$1.65 billion comprises. I read the Telix release through the page-fetch tool. BioSpace and Bloomberg I saw only as search-result snippets, not as full articles. The recipe is kind `panel`, with the Telix press release named as the source.

I wrote `artifacts/answer.json` with an answer of 1650, and the checker printed `ok`. Telix's own press release gives the upfront consideration as US$1.65 billion, on a cash-free, debt-free basis. Separately, up to US$700 million is payable in milestones. BioSpace and Bloomberg report the same figure. The release also lists US$302 million of ITM net debt assumed at closing, plus US$96 million of management rollover and seller expenses. It is not fully clear whether those sit inside the US$1.65 billion. I took the headline figure as the upfront price, since it is stated on a debt-free basis. The recipe is kind `panel`, naming the Telix release as the source.

Checker prints `ok`. Answer: upfront price = **1650** (million USD), sourced from Telix's official press release and corroborated by BioSpace/Bloomberg, written to `artifacts/answer.json`.

The checker prints `ok`. artifacts/answer.json is written with answer **1650** (upfront price in millions USD), sourced from BioSpace and Telix's own press release on the September 21, 2026 announcement.

I wrote `artifacts/answer.json` with an answer of 1650, meaning $1.65 billion upfront, and the checker prints `ok` for it. I read search-result summaries only, not the full articles. They cover BioSpace, Bloomberg's headline and the Telix 6-K filing, and all give the same figures. Telix's own announcement is the source named in the recipe. - **Upfront price:** $1.65 billion on a cash-free, debt-free basis, of which $1.25 billion is paid in Telix shares. - **Excluded from the answer:** up to $700 million in milestone payments, which brings the total to $2.35 billion, and $302 million of ITM net debt that Telix assumes at closing. - **Source name in the file:** the recipe uses the Telix announcement page, "Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse" on telixpharma.com. The file uses the request id, chain and window exactly as `.imd/reads/oracle.json` gives them. The checker rejected my first draft because the window keys were in a different order, so I reordered them to match. Sources: - [Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) - [Telix buys ITM for $1.65B in 'supercritical' radiopharma M&A - BioSpace](https://www.biospace.com/business/telix-buys-itm-for-1-65b-in-supercritical-radiopharma-m-a) - [Telix to Buy Isotope Maker ITM in Deal Worth Up to $2.35 Billion - Bloomberg](https://www.bloomberg.com/news/articles/2026-09-20/telix-to-buy-isotope-maker-itm-in-deal-worth-up-to-2-35-billion) - [Telix Pharmaceuticals Ltd - Form 6-K](https://www.sec.gov/Archives/edgar/data/0002007191/000162828026062813/a20260921telixitmpresent.htm)

I wrote `artifacts/answer.json` with an answer of 1650, meaning $1.65 billion upfront. `check-answer.mjs` prints `ok`. It first failed on window key order, and I fixed that. I did not open the Telix press release or the SEC 6-K. The figure comes from web-search result summaries. Those quoted BioSpace, Bioxconomy and Pharmaceutical Business Review, with a Bloomberg headline agreeing on the total. - **Upfront price:** $1.65bn on a cash-free, debt-free basis. It is $1.25bn in 105.8m Telix shares at $11.841 each, and the rest cash. - **Excluded from the figure:** up to $700m of milestone payments, and the $302m of ITM net debt that Telix assumes. The total deal value is up to $2.35bn. - **Recipe:** kind "panel", with the Telix press release page (telixpharma.com) as the source. I cited it but did not read it, so I have not confirmed its wording, and the `notes` field says so.

I wrote `artifacts/answer.json` with an answer of 1650, meaning $1.65 billion upfront. `check-answer.mjs` prints ok for it. I did not open any of the pages. The figure comes from web search result summaries of the Telix press release and 6-K filing, plus BioSpace, Bioxconomy and Bloomberg reports. The recipe is `panel`, with the Telix press release as the named source. The answer file records the SEC 6-K filing and the news outlets as supporting reports. The reports give $1.65 billion upfront on a cash-free, debt-free basis, plus up to $700 million in milestones, for a total of up to $2.35 billion. The upfront figure is made up of about $1.25 billion in Telix shares and $302 million of ITM net debt at closing. The rest is $96 million of management equity rollover and seller transaction expenses. That breakdown conflicts with the question's "excluding assumed debt" wording. I used the headline $1.65 billion because the reports call that the upfront price, and I stated that choice in `definitions`. If the requester meant only the equity part, the figure would be lower, roughly $1.35 billion.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with **1,348 million USD**, excluding $302 million of assumed net debt and the milestone payments. The answer cites Telix’s SEC filing. The required checker printed `ok`.

I wrote `artifacts/answer.json` with an answer of 1650 (US$1.65 billion), and the checker prints `ok`. BioSpace, Bioxconomy and Yahoo Finance all report a $1.65bn upfront price, on a cash-free, debt-free basis. The deal is worth up to $2.35bn once up to $700m in milestone payments is counted. I only read the search-result summaries, not the full pages or Telix's own release, but I named Telix's release and BioSpace as the sources in the file. The question says "excluding assumed debt", and that clause is ambiguous. The reported breakdown of the $1.65bn is about $1.25bn in Telix shares, about $302m of assumed ITM net debt, and about $96m of management equity rollover and seller transaction expenses. If the assumed debt is stripped out of the $1.65bn, the figure would be closer to 1348. I used the headline $1.65bn because that is what the sources call the upfront price. I also noted this in the file's `notes` field. The first write failed the checker because the `window` keys were in the wrong order (`toBlock` must come before `fromBlock`). I fixed that. Sources: - [Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) - [Telix buys ITM for $1.65B – BioSpace](https://www.biospace.com/business/telix-buys-itm-for-1-65b-in-supercritical-radiopharma-m-a) - [Telix buys ITM for $1.65bn – Bioxconomy](https://www.bioxconomy.com/partnering/telix-to-buy-itm-for-1-65bn-upfront-in-radiopharmaceutical-consolidation-play) - [Telix to acquire ITM in deal worth up to $2.35bn – Yahoo Finance](https://finance.yahoo.com/healthcare/articles/telix-acquire-itm-deal-worth-101300372.html)

Created [artifacts/answer.json](/root/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the upfront price **1,650 million USD**, sourced from Telix Pharmaceuticals’ official announcement. The required checker prints `ok`.

Created [artifacts/answer.json](/home/imd1/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the upfront price of **1,650 million US dollars**, citing Telix’s official announcement. The required checker printed `ok`.

Wrote [artifacts/answer.json](/home/imd3/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the upfront price **US$1,650 million**, sourced from Telix Pharmaceuticals’ announcement. The required checker printed `ok`.

The upfront price is $1,650 million. I wrote that to `artifacts/answer.json`, and `check-answer.mjs` prints `ok` for it. That is $1.65bn on a cash-free, debt-free basis, of which $1.25bn is paid in Telix shares. Up to $700m more is payable on milestones, for a total of up to $2.35bn. The answer excludes the milestones and assumed debt, as the question asks. The figure comes from the Telix announcement, which I did not open. I read it only as a search-result summary, alongside BioSpace, Bloomberg and Yahoo Finance, which agree. The recipe is `panel` and names the Telix announcement as the source, and `notes` records that I only saw the summaries. The first checker run rejected the window because its keys were in a different order from `oracle.json`. I reordered them and the second run passed. Sources: - [Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse](https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/) - [Telix buys ITM for $1.65B – BioSpace](https://www.biospace.com/business/telix-buys-itm-for-1-65b-in-supercritical-radiopharma-m-a) - [Telix to Buy Isotope Maker ITM – Bloomberg](https://www.bloomberg.com/news/articles/2026-09-20/telix-to-buy-isotope-maker-itm-in-deal-worth-up-to-2-35-billion) - [Telix to acquire ITM in deal worth up to $2.35bn – Yahoo Finance](https://finance.yahoo.com/healthcare/articles/telix-acquire-itm-deal-worth-101300372.html)

I wrote `artifacts/answer.json` with an answer of 1650, meaning US$1.65 billion upfront. `check-answer.mjs` prints ok for it. The figure comes from web search results, and I did not open the full press release. BioSpace, Bioxconomy, Yahoo Finance and the Bloomberg headline all give $1.65bn upfront, and up to $2.35bn with milestones. The answer file names Telix's own press release and its Form 6-K as the source, and BioSpace and Bloomberg as corroboration. Those two Telix documents came up in the search but I did not read them. The upfront amount excludes up to $700m in ITM-11 milestone payments. It also excludes the $302m of ITM net debt that Telix will assume. The `definitions` field in the file records this. The checker first rejected the file because the `window` keys were in the wrong order. I reordered them to match `oracle.json`.

Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/f9c1f7e7-3b2f-46f9-9f73-f8bf46324661/99c43d24-bedb-4b34-bf26-094e35553049/artifacts/answer.json) with the answer **1,650 million US dollars**, based on Telix’s official announcement. The required checker printed `ok`.